Alphabet Inc. acquired a new stake in Metsera Inc. (NASDAQ:MTSR - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,961,744 shares of the company's stock, valued at approximately $135,059,000. Metsera comprises about 8.6% of Alphabet Inc.'s portfolio, making the stock its 5th largest position. Alphabet Inc. owned about 4.72% of Metsera at the end of the most recent quarter.
Separately, New York State Common Retirement Fund purchased a new stake in Metsera during the first quarter worth $131,000.
Metsera Stock Performance
NASDAQ:MTSR traded up $0.57 during trading hours on Thursday, reaching $44.30. 688,607 shares of the company were exchanged, compared to its average volume of 758,151. The stock has a 50-day moving average of $30.12. Metsera Inc. has a twelve month low of $12.30 and a twelve month high of $46.43.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on MTSR shares. Wells Fargo & Company started coverage on shares of Metsera in a report on Friday, June 20th. They set an "overweight" rating and a $65.00 price target on the stock. Guggenheim increased their price target on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Metsera has an average rating of "Buy" and an average target price of $55.00.
Check Out Our Latest Analysis on Metsera
Metsera Company Profile
(
Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access